TWST
Twist Bioscience Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$124.72
−3.10%Aug 25, 2026, 07:55 UTC
Brandywine Managers LLC acquired a new position in Twist Bioscience Corporation, purchasing 20,970 shares valued at approximately $2.16 million during the second quarter, as disclosed in a Form 13F filing.
Source:Aug 20, 2026, 10:00 UTC
Anthropic published research showing its Claude models (Mythos Preview and Opus 4.8) autonomously ran protein-design campaigns, a key step in drug discovery, with designs yielding working molecules on 14 out of 15 targets at success rates above industry norms.
Aug 19, 2026, 20:11 UTC
Anthropic named Twist Bioscience Corp an independent evaluator in a new AI-driven protein design campaign.
Source:Aug 6, 2026, 07:14 UTC
Twist Bioscience's share price rose 10.3% during mid-day trading on Wednesday after Piper Sandler raised its price target.
Source:Aug 4, 2026, 20:01 UTC
Twist Bioscience Corporation announced the commencement of an underwritten public offering of $250.0 million of its common stock, with an option for underwriters to purchase an additional $37.5 million of shares.
Aug 3, 2026, 11:15 UTC
Twist Bioscience Corporation announced its financial results and business highlights for the third quarter of fiscal 2026 ended June 30, 2026.